{"id":"https://openalex.org/W7162575554","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.4110","title":"Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-arm, phase II study.","display_name":"Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-arm, phase II study.","alternate_titles":[],"publication_year":2026,"publication_date":"2026-05-27","ids":{"openalex":"https://openalex.org/W7162575554","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.4110"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2026.44.16_suppl.4110","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.4110","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4110","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W7162575554"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5137115648","display_name":"Yiming Zhao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yiming Zhao","raw_affiliation_strings":["Fudan University Shanghai Cancer Center, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fudan University Shanghai Cancer Center, Shanghai, China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038584729","display_name":"Longrong Wang","orcid":"https://orcid.org/0000-0003-1470-1425","observed_orcids":["https://orcid.org/0000-0003-1470-1425"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Longrong Wang","raw_affiliation_strings":["Fudan University Shanghai Cancer Center, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fudan University Shanghai Cancer Center, Shanghai, China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038105875","display_name":"\u6bdb\u5cb8\u8363","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Anrong Mao","raw_affiliation_strings":["Fudan University Shanghai Cancer Center, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fudan University Shanghai Cancer Center, Shanghai, China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004844925","display_name":"Weiping Zhu","orcid":"https://orcid.org/0000-0002-8856-5609","observed_orcids":["https://orcid.org/0000-0002-8856-5609"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Weiping Zhu","raw_affiliation_strings":["Fudan University Shanghai Cancer Center, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fudan University Shanghai Cancer Center, Shanghai, China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5127404399","display_name":"Ti Zhang","orcid":"https://orcid.org/0000-0002-8759-4395","observed_orcids":["https://orcid.org/0000-0002-8759-4395"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ti Zhang","raw_affiliation_strings":["Fudan University Shanghai Cancer Center, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fudan University Shanghai Cancer Center, Shanghai, China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136192915","display_name":"Qi Pan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Qi Pan","raw_affiliation_strings":["Liver Surgery Department, Fudan University Shanghai Cancer Center, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Liver Surgery Department, Fudan University Shanghai Cancer Center, Shanghai, China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101832543","display_name":"Lu Wang","orcid":"https://orcid.org/0000-0002-1352-5848","observed_orcids":["https://orcid.org/0000-0002-1352-5848"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Lu Wang","raw_affiliation_strings":["Fudan University Shanghai Cancer Center, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fudan University Shanghai Cancer Center, Shanghai, China","institution_ids":["https://openalex.org/I4210093194"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210093194"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"44","issue":"16_suppl","first_page":"4110","last_page":"4110"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11364","display_name":"Cholangiocarcinoma and Gallbladder Cancer Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11364","display_name":"Cholangiocarcinoma and Gallbladder Cancer Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12460","display_name":"Pediatric Hepatobiliary Diseases and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10518","display_name":"Gallbladder and Bile Duct Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tislelizumab","display_name":"tislelizumab","score":0.9570000171661377},{"id":"https://openalex.org/keywords/donafenib","display_name":"donafenib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/gemox","display_name":"GEMOX","score":0.9139999747276306},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.902999997138977},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":1.0},{"id":"https://openalex.org/keywords/advanced-biliary-tract-cancer","display_name":"advanced biliary tract cancer","score":0.9509999752044678},{"id":"https://openalex.org/keywords/cholangiocarcinoma","display_name":"cholangiocarcinoma","score":0.8629999756813049},{"id":"https://openalex.org/keywords/gallbladder-cancer","display_name":"gallbladder cancer","score":0.9610000252723694},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6850000023841858},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7990000247955322},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5009999871253967},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9290000200271606},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.824999988079071},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.6060000061988831},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.5609999895095825},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.6140000224113464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9663000106811523},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.8119000196456909},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.7475000023841858},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.661300003528595},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5188000202178955},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4993000030517578},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.49549999833106995},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4426000118255615},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4318000078201294},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.4088999927043915},{"id":"https://openalex.org/C2776534502","wikidata":"https://www.wikidata.org/wiki/Q977787","display_name":"Gallbladder cancer","level":3,"score":0.39649999141693115},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.35249999165534973},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.35010001063346863},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34880000352859497},{"id":"https://openalex.org/C2777148285","wikidata":"https://www.wikidata.org/wiki/Q64386","display_name":"Gallbladder","level":2,"score":0.3370000123977661},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.32829999923706055},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.3138999938964844},{"id":"https://openalex.org/C2775982439","wikidata":"https://www.wikidata.org/wiki/Q3562150","display_name":"Biliary tract","level":2,"score":0.30149999260902405},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2838999927043915},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.2808000147342682},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.2727000117301941}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2026.44.16_suppl.4110","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.4110","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4110","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4405134892","https://openalex.org/W4283789129","https://openalex.org/W4364351780","https://openalex.org/W2094501197","https://openalex.org/W2600759207","https://openalex.org/W2589965838","https://openalex.org/W7126183606","https://openalex.org/W2065756402","https://openalex.org/W4391090979","https://openalex.org/W2361917953"],"abstract_inverted_index":{"4110":[0],"Background:":[1],"Advanced":[2],"biliary":[3],"tract":[4],"cancer":[5,88],"(BTC)":[6],"progresses":[7],"rapidly":[8],"and":[9,24,29,42,59,65,101,126,139,194,207,215,227,281,296,311],"has":[10,38],"a":[11,15,70,187,299],"poor":[12],"prognosis,":[13],"with":[14,114,186],"5-year":[16],"survival":[17,248],"rate":[18,169,219,249],"of":[19,61,99,157,190,263],"less":[20],"than":[21],"5%.":[22],"Gemcitabine":[23],"oxaliplatin":[25,141],"(GEMOX)":[26],"plus":[27,63,294],"tislelizumab":[28,64,115,295],"donafenib":[30,122,297],"as":[31,298],"the":[32,57,166,216,261,269],"first-line":[33,237],"treatment":[34,302],"for":[35,304],"advanced":[36,305],"BTC":[37,306],"confirmed":[39],"good":[40],"safety":[41,60],"preliminary":[43],"efficacy":[44,58,310],"in":[45],"our":[46],"phase":[47,72],"I":[48],"study":[49,52],"(NCT04979663).":[50],"This":[51,68],"aimed":[53],"to":[54,130,179],"further":[55],"evaluate":[56],"GEMOX":[62,127,293],"donafenib.":[66],"Methods:":[67],"is":[69],"single-arm,":[71],"II":[73],"trial":[74,314],"(NCT05668884).":[75],"Patients":[76,111],"were":[77,81,92,112,184,224,275,289],"enrolled":[78,185],"if":[79],"they":[80],"18-75":[82],"years":[83],"old,":[84],"had":[85,95,102,199,204,210,256],"stage":[86],"III/IV":[87],"(AJCC":[89],"8th":[90],"Edition),":[91],"Child-Pugh":[93],"A/B,":[94],"an":[96],"ECOG":[97],"PS":[98],"0-1,":[100],"received":[103],"no":[104],"prior":[105],"systemic":[106],"therapy":[107],"or":[108,152,155],"tumor-related":[109],"surgery.":[110],"administrated":[113],"(200":[116],"mg":[117],"IV":[118,136,144],"on":[119,137,145],"d1":[120,138],"Q3W),":[121],"(200mg":[123],"PO":[124],"BID)":[125],"(Q3W":[128],"up":[129],"8":[131],"cycles:":[132],"gemcitabine":[133],"1000":[134],"mg/m\u00b2":[135,143],"8,":[140],"100":[142],"d1).":[146],"Treatment":[147],"continued":[148],"until":[149],"disease":[150,217],"progression":[151],"unacceptable":[153],"toxicity":[154],"withdrawal":[156],"consent":[158],"whichever":[159],"occurred":[160],"first.":[161],"The":[162,213,239],"primary":[163],"endpoint":[164],"was":[165,242,250,267],"objective":[167],"response":[168],"(ORR)":[170],"assessed":[171],"by":[172,221],"RECIST":[173,222],"v1.1.":[174],"Results:":[175],"From":[176],"December":[177],"2022":[178],"October":[180],"2025,":[181],"47":[182],"patients":[183,198,203,232,255,307],"mean":[188],"age":[189],"60.8":[191],"(18":[192],"females":[193],"29":[195],"males),":[196],"35":[197],"intrahepatic":[200],"cholangiocarcinoma,":[201],"11":[202],"gallbladder":[205],"carcinoma":[206],"1":[208],"patient":[209],"perihilar":[211],"cholangiocarcinoma.":[212],"ORR":[214],"control":[218],"(DCR)":[220],"1.1":[223],"38.3%":[225],"(18/47)":[226],"93.6%":[228],"(44/47),":[229],"respectively.":[230],"2":[231],"underwent":[233],"subsequent":[234],"surgery":[235],"after":[236],"treatment.":[238],"median":[240],"PFS":[241],"12.1":[243],"months":[244],"(95%CI:":[245,252],"5.1-19.1),":[246],"1-year":[247],"57%":[251],"38-76).":[253],"All":[254],"treatment-related":[257],"adverse":[258],"events":[259],"(TRAEs),":[260],"incidence":[262],"grade":[264,272,286],"3-4":[265,273],"TRAEs":[266,274,288],"46.8%,":[268],"most":[270],"common":[271],"rash":[276],"(6/47,12.8%),":[277],"thrombocytopenia":[278],"(5/47,10.6":[279],"%)":[280],"fever":[282],"(3/47,":[283],"6.4%).":[284],"No":[285],"5":[287],"observed":[290],".":[291,317],"Conclusions:":[292],"first":[300],"line":[301],"option":[303],"shows":[308],"favorable":[309],"tolerability.":[312],"Clinical":[313],"information:":[315],"NCT05668884":[316]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7162575554","counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2026-05-28T00:00:00"}
